Deutetrabenazine

CMS has selected 15 new drugs for the next round of Medicare Part D price negotiations, according to a press release from HHS.

CHICAGO — Adults with tardive dyskinesia prescribed deutetrabenazine had better adherence and were less likely to discontinue treatment compared with those on valbenazine, although the differences were not statistically significant.

Austedo did not efficaciously treat tics linked to Tourette syndrome in children and adolescents, according to results of a randomized clinical trial published in JAMA Network Open.